Core Insights - Myriad Genetics reported revenue of $213.1 million for the quarter ended June 2025, marking a year-over-year increase of 0.8% and exceeding the Zacks Consensus Estimate of $201.9 million by 5.55% [1] - The company achieved an EPS of $0.05, which is consistent with the EPS from the same period last year, and delivered a significant EPS surprise of 600% compared to the consensus estimate of -$0.01 [1] Revenue Breakdown by Core Product - Prenatal revenue reached $47.6 million, slightly below the average estimate of $49.93 million, reflecting a year-over-year increase of 10.7% [4] - Hereditary Cancer revenue was $96.3 million, surpassing the average estimate of $88.37 million, with a year-over-year growth of 5.3% [4] - Pharmacogenomics revenue totaled $37.8 million, exceeding the average estimate of $32.08 million, but showing a year-over-year decline of 12.1% [4] - Tumor Profiling revenue was reported at $31.4 million, closely aligning with the average estimate of $31.31 million, and indicating a year-over-year decrease of 3.7% [4] Stock Performance - Myriad's shares have declined by 24.8% over the past month, contrasting with a 1% increase in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 4 (Sell), suggesting potential underperformance relative to the broader market in the near term [3]

Core Insights - NNN REIT reported revenue of $226.5 million for the quarter ended June 2025, reflecting a year-over-year increase of 4.8% and surpassing the Zacks Consensus Estimate of $225.55 million by 0.42% [1] - The company's EPS for the quarter was $0.85, compared to $0.58 in the same quarter last year, indicating a significant improvement and an EPS surprise of 1.19% over the consensus estimate of $0.84 [1] Revenue Breakdown - Rental income was reported at $226.5 million, exceeding the four-analyst average estimate of $225.07 million, with a year-over-year change of +4.8% [4] - Interest and other income from real estate transactions was reported at $0.3 million, which fell short of the three-analyst average estimate of $0.59 million, representing a year-over-year decline of 54.8% [4] Stock Performance - Over the past month, shares of NNN REIT have returned -0.7%, while the Zacks S&P 500 composite has increased by 1% [3] - The stock currently holds a Zacks Rank 2 (Buy), suggesting potential for outperformance against the broader market in the near term [3]

Core Insights - Analysts project Royalty Pharma (RPRX) will report quarterly earnings of $1.10 per share, reflecting a 14.6% year-over-year increase [1] - Revenue is expected to reach $686.22 million, marking a 12.9% increase from the same quarter last year [1] - The consensus EPS estimate has remained unchanged over the last 30 days, indicating a reevaluation of initial estimates by analysts [1] Revenue Estimates - 'Portfolio Receipts- Royalty Receipts- Products- Cystic fibrosis franchise' is projected to reach $206.12 million, a 5.8% increase year-over-year [4] - 'Portfolio Receipts- Royalty Receipts- Products- Tysabri' is estimated at $53.90 million, indicating a 15.6% decrease from the prior year [4] - 'Portfolio Receipts- Royalty Receipts- Products- Imbruvica' is expected to be $39.81 million, reflecting a 19% decrease year-over-year [5] - 'Portfolio Receipts- Royalty Receipts- Products- Xtandi' is forecasted at $42.75 million, a 10.7% increase year-over-year [5] - 'Portfolio Receipts- Royalty Receipts- Products- Promacta' is anticipated to reach $39.51 million, showing a 29.5% increase from the previous year [5] Additional Product Estimates - 'Portfolio Receipts- Royalty Receipts- Products- Cabometyx/Cometriq' is projected at $19.64 million, a 17.3% increase year-over-year [6] - 'Portfolio Receipts- Royalty Receipts- Products- Evrysdi' is expected to be $31.21 million, indicating a 25.2% increase from the prior year [6] - 'Portfolio Receipts- Royalty Receipts- Products- Trodelvy' is forecasted at $10.87 million, reflecting a 4.6% increase year-over-year [7] - 'Portfolio Receipts- Royalty Receipts- Products- Trelegy' is estimated at $57.04 million, indicating a 17.6% increase year-over-year [7] - 'Portfolio Receipts- Royalty Receipts- Products- Tremfya' is projected to reach $38.47 million, reflecting a 28.6% increase year-over-year [8] Stock Performance - Shares of Royalty Pharma have increased by 6.4% in the past month, outperforming the Zacks S&P 500 composite, which moved up by 1% [8] - The company holds a Zacks Rank 3 (Hold), suggesting it is expected to mirror overall market performance in the near future [8]

Wall Street analysts forecast that Insmed (INSM) will report quarterly loss of -$1.30 per share in its upcoming release, pointing to a year-over-year increase of 33%. It is anticipated that revenues will amount to $103.42 million, exhibiting an increase of 14.5% compared to the year-ago quarter. The current level reflects a downward revision of 1.1% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their i ...

Wall Street analysts expect Western Midstream (WES) to post quarterly earnings of $0.82 per share in its upcoming report, which indicates a year-over-year decline of 15.5%. Revenues are expected to be $941.48 million, up 4% from the year-ago quarter. Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted downward by 0.5% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period. Ahead of a company's ear ...

Group 1 - Sitio Royalties reported $145.66 million in revenue for Q2 2025, a year-over-year decline of 13.6% [1] - The EPS for the same period was $0.08, down from $0.15 a year ago, but exceeded the consensus estimate of $0.04 by 100% [1] - The reported revenue surpassed the Zacks Consensus Estimate of $136.5 million, resulting in a surprise of +6.71% [1] Group 2 - Sitio Royalties' average daily combined production volume was 41,879.00 BOE/D, slightly above the average estimate of 40,916.75 BOE/D [4] - Average realized prices for natural gas were $1.43, significantly lower than the $2.09 average estimate [4] - Average realized prices for crude oil were $63.03, closely aligning with the estimated $62.98 [4] - Average realized prices for NGLs were $22.57, exceeding the $16.91 average estimate [4] - Revenue from NGLs was $19.98 million, surpassing the two-analyst average estimate of $14.7 million [4] Group 3 - Over the past month, shares of Sitio Royalties returned -4.2%, while the Zacks S&P 500 composite increased by +0.6% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market [3]

Core Insights - Archrock Inc. reported revenue of $383.15 million for the quarter ended June 2025, marking a year-over-year increase of 41.6% and exceeding the Zacks Consensus Estimate of $360.26 million by 6.36% [1] - The company's EPS for the same period was $0.39, up from $0.25 a year ago, and also surpassed the consensus EPS estimate of $0.37 by 5.41% [1] Revenue Breakdown - Aftermarket services revenue was $64.83 million, significantly higher than the two-analyst average estimate of $50.24 million, reflecting a year-over-year change of 43.9% [4] - Contract operations revenue reached $318.33 million, exceeding the average estimate of $309.38 million based on two analysts, with a year-over-year increase of 41.2% [4] Gross Margin Analysis - Gross margin for aftermarket services was reported at $14.94 million, compared to the estimated $11.63 million by two analysts [4] - Gross margin for contract operations was $222.18 million, slightly above the average estimate of $216.61 million based on two analysts [4] Stock Performance - Over the past month, Archrock Inc. shares have returned -9%, while the Zacks S&P 500 composite has seen a +0.6% change [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]

Core Insights - Postal Realty Trust (PSTL) reported a revenue of $23.35 million for the quarter ended June 2025, marking a 29.4% increase year-over-year [1] - The earnings per share (EPS) was $0.33, significantly up from $0.02 in the same quarter last year [1] - The revenue exceeded the Zacks Consensus Estimate of $22.49 million by 3.84%, while the EPS also surpassed the consensus estimate of $0.30 by 10% [1] Revenue Breakdown - Total revenues from rental income were $22.73 million, exceeding the average estimate of $21.78 million from three analysts, reflecting a year-over-year increase of 30.9% [4] - Fee and other revenues were reported at $0.62 million, which was below the average estimate of $0.67 million, indicating a year-over-year decline of 9.5% [4] Financial Performance Metrics - The diluted net income per share was reported at $0.12, compared to the estimated $0.07 from three analysts [4] - Over the past month, shares of Postal Realty Trust have returned -8.7%, contrasting with the Zacks S&P 500 composite's increase of 0.6% [3] - The stock currently holds a Zacks Rank 2 (Buy), suggesting potential outperformance against the broader market in the near term [3]

Core Viewpoint - Analysts project that ConocoPhillips (COP) will report quarterly earnings of $1.36 per share, reflecting a year-over-year decline of 31.3%, while revenues are expected to reach $14.93 billion, an increase of 5.6% from the same quarter last year [1]. Earnings Estimates - Over the past 30 days, the consensus EPS estimate has been revised upward by 12.8%, indicating a collective reassessment by analysts of their initial forecasts [2]. - Changes in earnings estimates are crucial for predicting investor reactions, with empirical studies showing a strong correlation between earnings estimate revisions and short-term stock price performance [3]. Revenue Projections - Analysts estimate that 'Revenues- Sales and other operating revenues' will reach $14.68 billion, representing a 7.8% increase from the prior-year quarter [5]. - The projected 'Revenues- Equity in earnings of affiliates' is estimated at $259.20 million, indicating a decline of 35.7% from the year-ago quarter [5]. Specific Revenue Metrics - 'Sales and Other Operating Revenue- Natural gas liquids' is projected to be $735.48 million, up 11.1% from the previous year [6]. - 'Sales and Other Operating Revenue- Natural gas' is expected to reach $1.21 billion, reflecting a 2.8% increase from the prior-year quarter [6]. - 'Sales and Other Operating Revenue- Canada' is anticipated to be $884.24 million, down 6% from the year-ago quarter [7]. - 'Sales and Other Operating Revenue- Europe, Middle East and North Africa' is projected at $1.37 billion, indicating a 5.6% increase from the prior-year quarter [7]. - 'Sales and Other Operating Revenue- Lower 48' is expected to be $9.79 billion, reflecting an 8.2% increase from the prior-year quarter [8]. Production Estimates - Total production per day is estimated to reach 2,362.71 thousand barrels of oil equivalent, compared to 1,945.00 thousand barrels of oil equivalent from the previous year [8]. - 'Natural gas liquids produced per day - Total company' is projected at 399.43 thousand barrels of oil, up from 295.00 thousand barrels of oil year-over-year [9]. - 'Crude oil produced per day - Total company' is expected to be 1,153.05 thousand barrels of oil, compared to 955.00 thousand barrels of oil from the previous year [10]. - 'Bitumen produced per day' is projected at 146.05 thousand barrels of oil, up from 133.00 thousand barrels of oil year-over-year [10]. Stock Performance - Shares of ConocoPhillips have seen a decline of 1% over the past month, contrasting with a 0.6% increase in the Zacks S&P 500 composite [10].

The upcoming report from DigitalOcean Holdings, Inc. (DOCN) is expected to reveal quarterly earnings of $0.47 per share, indicating a decline of 2.1% compared to the year-ago period. Analysts forecast revenues of $216.62 million, representing an increase of 12.5% year over year. Over the last 30 days, there has been a downward revision of 1.8% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecas ...